MYC and cancer: RiBi overoccurrence is a controllable target of cancer; rRNA accounts for about 80% of total RNA and RiBi requires a large number of nucleotides, mTORC1 or c-MYC oncogenic signaling pathway overactivation while upregulating RiBi and nucleotide de novo synthesis [18].